IndustryCompany release

NextCure's Avere merger financing rises to about $820M as SEC clears S-4 and vote is set for Dec 9

🇺🇸 NextCure, Inc. (NXTC) · Tue 10 Nov 2026

On November 10, 2026, NextCure reported Q3 results and said the financing for its proposed merger with Avere Therapeutics, developer of oral IL-23 therapy AVR-001, had grown to roughly $820 million. The SEC declared the S-4 effective on November 6, and stockholders vote on December 9, 2026. NextCure also handed the LNCB74 IND to LigaChem, restructured, and ended its SIM0505 study treatment, leaving $8.7 million in cash.

Company's press release (SEC filing): NextCure, Inc. ↗

Brief written by VigiEye from the company's press release filed with the SEC. Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →